Hong DS - Search Results

1

PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.

Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS, Naing A, Falchook GS, Moroney JW, Piha-Paul SA, Wheler JJ, Moulder SL, Fu S, Kurzrock R. Janku F, et al. Among authors: hong ds. Mol Cancer Ther. 2011 Mar;10(3):558-65. doi: 10.1158/1535-7163.MCT-10-0994. Epub 2011 Jan 7. Mol Cancer Ther. 2011. PMID: 21216929 Free PMC article.

2

Interleukin-6 and its receptor in cancer: implications for translational therapeutics.

Hong DS, Angelo LS, Kurzrock R. Hong DS, et al. Cancer. 2007 Nov 1;110(9):1911-28. doi: 10.1002/cncr.22999. Cancer. 2007. PMID: 17849470 Free article. Review.

3

Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib.

Hong D, Ye L, Gagel R, Chintala L, El Naggar AK, Wright J, Kurzrock R. Hong D, et al. Mol Cancer Ther. 2008 May;7(5):1001-6. doi: 10.1158/1535-7163.MCT-07-2422. Epub 2008 Apr 29. Mol Cancer Ther. 2008. PMID: 18445656

4

Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib.

Hong DS, Reddy SB, Prieto VG, Wright JJ, Tannir NM, Cohen PR, Diwan AH, Evans HL, Kurzrock R. Hong DS, et al. Arch Dermatol. 2008 Jun;144(6):779-82. doi: 10.1001/archderm.144.6.779. Arch Dermatol. 2008. PMID: 18559769

5

Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers.

Braiteh F, Soriano AO, Garcia-Manero G, Hong D, Johnson MM, Silva Lde P, Yang H, Alexander S, Wolff J, Kurzrock R. Braiteh F, et al. Clin Cancer Res. 2008 Oct 1;14(19):6296-301. doi: 10.1158/1078-0432.CCR-08-1247. Clin Cancer Res. 2008. PMID: 18829512 Free PMC article. Clinical Trial.

6

Survival of patients in a Phase 1 Clinic: the M. D. Anderson Cancer Center experience.

Wheler J, Tsimberidou AM, Hong D, Naing A, Jackson T, Liu S, Feng L, Kurzrock R. Wheler J, et al. Cancer. 2009 Mar 1;115(5):1091-9. doi: 10.1002/cncr.24018. Cancer. 2009. PMID: 19165805 Free article.

7

Clinical outcomes and factors predicting development of venous thromboembolic complications in patients with advanced refractory cancer in a Phase I Clinic: the M. D. Anderson Cancer Center experience.

Vemulapalli S, Chintala L, Tsimberidou AM, Dhillon N, Lei X, Hong D, Kurzrock R. Vemulapalli S, et al. Am J Hematol. 2009 Jul;84(7):408-13. doi: 10.1002/ajh.21423. Am J Hematol. 2009. PMID: 19437507 Free article.

8

Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas.

Stewart DJ, Issa JP, Kurzrock R, Nunez MI, Jelinek J, Hong D, Oki Y, Guo Z, Gupta S, Wistuba II. Stewart DJ, et al. Clin Cancer Res. 2009 Jun 1;15(11):3881-8. doi: 10.1158/1078-0432.CCR-08-2196. Epub 2009 May 26. Clin Cancer Res. 2009. PMID: 19470736 Clinical Trial.

9

Phase 1 first-in-human clinical study of S-trans,trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors.

Tsimberidou AM, Rudek MA, Hong D, Ng CS, Blair J, Goldsweig H, Kurzrock R. Tsimberidou AM, et al. Cancer Chemother Pharmacol. 2010 Jan;65(2):235-41. doi: 10.1007/s00280-009-1027-4. Cancer Chemother Pharmacol. 2010. PMID: 19484470 Clinical Trial.

10

A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer.

Moulder S, Dhillon N, Ng C, Hong D, Wheler J, Naing A, Tse S, La Paglia A, Dorr R, Hersh E, Boytim M, Kurzrock R. Moulder S, et al. Invest New Drugs. 2010 Oct;28(5):634-40. doi: 10.1007/s10637-009-9273-1. Epub 2009 Jun 6. Invest New Drugs. 2010. PMID: 19499186 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

519 results

Search Page

Filters